{"id":827952,"date":"2026-07-28T00:03:10","date_gmt":"2026-07-28T00:03:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/827952\/"},"modified":"2026-07-28T00:03:10","modified_gmt":"2026-07-28T00:03:10","slug":"optometrists-urged-to-be-on-lookout-for-link-between-medicines-eye-disease","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/827952\/","title":{"rendered":"Optometrists urged to be on lookout for link between medicines, eye disease"},"content":{"rendered":"<p>The Therapeutic Goods Administration (TGA) has issued a safety update about a potential association between glucagon-like peptide-1 receptor agonist medicines \u2013 commonly known as GLP-1 RAs \u2013 and non-arteritic anterior ischaemic optic neuropathy (NAION).<\/p>\n<p>NAION is a rare but serious condition that can cause sudden and potentially permanent vision loss. There is currently no treatment shown to improve visual acuity outcomes following NAION.<\/p>\n<p>GLP-1 RA medicines are primarily used to manage type 2 diabetes and obesity. Products currently marketed in Australia include:<br \/>\u2022 Trulicity (dulaglutide)<br \/>\u2022 Ozempic and Wegovy (semaglutide)<br \/>\u2022 Mounjaro (tirzepatide)<br \/>\u2022 Saxenda (liraglutide)<\/p>\n<p>In a statement, Optometry Australia (OA) said the product Information for these medicines had been updated to include warnings about reported cases of NAION.<\/p>\n<p>The TGA advises that sudden vision loss, including partial loss of vision, requires urgent ophthalmological assessment.<\/p>\n<p>What optometrists should do, according to the OA:<\/p>\n<p>\u2022 remain alert to the updated warnings and ask patients presenting with sudden or unexplained vision loss whether they are currently using, or have recently used, a GLP-1 RA medicine;<\/p>\n<p>\u2022 treat sudden partial or complete vision loss as an ocular emergency and undertake an appropriate and timely clinical assessment;<\/p>\n<p>\u2022 urgently refer patients with suspected NAION for ophthalmological examination and management, in accordance with established emergency referral pathways;<\/p>\n<p>\u2022 promptly communicate relevant clinical findings to the patient\u2019s ophthalmologist, general practitioner and prescribing practitioner;<\/p>\n<p>\u2022 advise patients not to delay urgent assessment while waiting to speak with their usual healthcare provider;<\/p>\n<p>\u2022 document the patient\u2019s medication history, symptoms, examination findings, advice, referrals and communication with other practitioners; and<\/p>\n<p>\u2022 report suspected medicine-related adverse events to the TGA.<\/p>\n<p>For semaglutide medicines, the updated product Information states that treatment should be discontinued if NAION is confirmed.<\/p>\n<p>OA said decisions about discontinuing or changing a patient\u2019s medicine should be coordinated with the prescribing practitioner, unless immediate action is otherwise clinically required within the optometrist\u2019s scope of practice.<\/p>\n<p>The TGA also notes that an anatomical predisposition sometimes described as a \u201cdisc at risk\u201d may be assessed by an optometrist or ophthalmologist.<\/p>\n<p>However, the alert does not establish a requirement for routine screening of every asymptomatic person taking a GLP-1 RA. Clinical assessment and follow-up should be based on the individual patient\u2019s presentation, ocular findings and broader risk profile.<\/p>\n<p>Patients using a GLP-1 RA should be advised to seek urgent medical attention if they experience sudden vision loss or a sudden partial loss of vision.<\/p>\n<p>OA said members seeking advice about their professional responsibilities or the management of a particular situation could contact the Optometry Advisor Help Desk on 1800 678 662 or email OAhelpdesk@optometry.org.au.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"The Therapeutic Goods Administration (TGA) has issued a safety update about a potential association between glucagon-like peptide-1 receptor&hellip;\n","protected":false},"author":2,"featured_media":827953,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,137],"class_list":["post-827952","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/827952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=827952"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/827952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/827953"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=827952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=827952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=827952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}